Feedback / Questions
OPN-6602 - Opna Bio
https://www.businesswire.com/news/home/20240826690075/en/Opna-Bio-Doses-First-Patient-in-Phase-1-Study-in-Multiple-Myeloma-with-OPN-6602-an-EP300CBP-Bromodomain-Inhibitor
Aug 26, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next